UroGen Pharma Announced Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it has commenced an underwritten